Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MICRO-K vs CALCIUM GLUCONATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium is the principal intracellular cation, essential for maintaining cellular tonicity, electrical neutrality, and enzymatic reactions. It modulates neuromuscular transmission, cardiac contractility, and acid-base balance.
Calcium gluconate dissociates to provide calcium ions, which are essential for nerve impulse transmission, muscle contraction, cardiac function, and blood coagulation. It acts as a mineral electrolyte replenisher.
Treatment of hypokalemia,Prevention of hypokalemia in patients at risk (e.g., on diuretics, digitalis)
Emergency treatment of hypocalcemia,Cardiac resuscitation (e.g., hyperkalemia, calcium channel blocker overdose, beta-blocker overdose),Treatment of hypermagnesemia,Treatment of acute symptomatic hypocalcemic tetany,Off-label: Prevention of hypocalcemia during massive blood transfusion, adjunctive treatment of lead poisoning (calcium EDTA), and treatment of fluoride poisoning
Oral: 20-40 m Eq (1-2 capsules) two to four times daily; maximum 100 m Eq/day. Each capsule contains 8 m Eq (600 mg) of potassium chloride in a wax matrix extended-release formulation.
Intravenous: 1-2 grams (10-20 m L of 10% solution) administered slowly over 5-10 minutes. May repeat based on serum calcium levels.
Not applicable; potassium is an electrolyte with no true elimination half-life; whole-body turnover half-life is approximately 12-24 hours, clinically relevant for dosing intervals.
Rapid distribution half-life ~5-10 min; terminal half-life 3-6 hours due to redistribution and renal excretion; clinically, effect duration is short (1-2 hours) due to rapid redistribution into bone and other tissues.
Potassium ions are not metabolized; they are primarily excreted unchanged by the kidneys (90%), with minor losses via feces and sweat.
Calcium gluconate is not metabolized. It dissociates to release calcium ions, which are distributed in the body and excreted primarily via the kidneys. The gluconate moiety is metabolized via the Krebs cycle.
Renal: approximately 90% of absorbed potassium is excreted in urine; biliary/fecal: less than 10% eliminated via feces.
Primarily renal (calcium is filtered and reabsorbed); negligible biliary/fecal. >98% of body calcium is in bone; excretion is complex and homeostatically regulated.
None; potassium is not significantly bound to plasma proteins.
Approximately 45% bound to albumin; remaining free ionized calcium is the active form.
0.5-0.7 L/kg; total body water distribution; clinically indicates extensive intracellular uptake (98% intracellular).
0.6-1.0 L/kg (distributes into extracellular fluid and bone; increases with bone turnover).
Oral: approximately 80-90% for Micro-K (extended-release); absorption occurs in small intestine.
IV: 100%; IM: poor and erratic (not recommended); oral: ~20-30% (limited by absorption and binding, not used for urgent hypocalcemia).
e GFR ≥60 m L/min: No adjustment. e GFR 30-59: Reduce dose by 25-50% and monitor potassium. e GFR 15-29: Reduce dose by 50-75% and monitor potassium. e GFR <15: Avoid use or use with extreme caution; maximum 20 m Eq/day with frequent monitoring.
No specific dose adjustment for renal impairment; however, caution in severe renal failure (GFR <30 m L/min) due to risk of hypercalcemia. Monitor serum calcium closely.
No specific dosing adjustments recommended for hepatic impairment. Monitor potassium levels as hepatic disease may affect potassium homeostasis.
No adjustment required for hepatic impairment.
Oral: <1 year: 1-2 m Eq/kg/day divided 2-4 times. 1-18 years: 1-3 m Eq/kg/day divided 2-4 times; maximum 100 m Eq/day. Extended-release capsules not recommended for children unable to swallow whole capsules.
Neonates and infants: 100-200 mg/kg/dose (1-2 m L/kg of 10% solution) IV slowly, maximum 2 g; children: 1-2 g/dose IV, maximum 2 g. Dilute to 50 mg/m L (5% solution) for IV administration.
Start at low end of dosing range (20-40 m Eq/day) due to decreased renal function; maximum 100 m Eq/day. Monitor renal function and potassium levels closely.
Start at lower end of dosing range (e.g., 1 gram IV) due to increased risk of hypercalcemia and potential underlying renal insufficiency. Monitor calcium levels and cardiac function.
None
No FDA black box warning.
Hyperkalemia risk, especially in patients with renal impairment, diabetes, or those receiving potassium-sparing diuretics, ACE inhibitors, or ARBs,Suspect gastrointestinal obstruction or perforation with slow-release formulations; caution in patients with severe GI disorders,Use with caution in patients with cardiac disease, particularly those on digoxin,Monitor serum potassium levels regularly
Risk of hypercalcemia; monitor serum calcium levels closely during therapy.,Risk of cardiac arrhythmias, especially if administered too rapidly or in patients receiving digoxin.,Avoid extravasation; may cause severe tissue necrosis (treat with hyaluronidase).,Use caution in renal impairment, sarcoidosis, or history of renal calculi.,Concomitant use with thiazide diuretics may increase risk of hypercalcemia.
Hyperkalemia (serum potassium >5.5 m Eq/L),Renal failure or severe renal impairment (e.g., oliguria, anuria),Addison's disease,Acute dehydration,Concomitant use with potassium-sparing diuretics (e.g., amiloride, spironolactone, triamterene),Concomitant use with eplerenone,Solid dosage forms in patients with delayed gastric emptying or esophageal compression
Hypercalcemia,Severe renal failure (relative, use with caution),Patients with ventricular fibrillation (use during cardiopulmonary resuscitation may be indicated),Digoxin toxicity (relative; may exacerbate arrhythmias, use with extreme caution)
Avoid high-potassium foods (e.g., bananas, oranges, spinach, potatoes, tomatoes) and potassium-based salt substitutes. Consuming large amounts of these may increase risk of hyperkalemia.
Avoid high-calcium foods (dairy, fortified cereals) if hypercalcemia is a concern; oxalate-rich foods (spinach, rhubarb) may reduce absorption; do not take within 2 hours of iron or tetracycline antibiotics.
Potassium chloride (Micro-K) is not associated with major congenital malformations. Normal maternal serum potassium levels are required for fetal development. Hypokalemia or hyperkalemia may increase risks. No trimester-specific risks documented.
FDA Pregnancy Category C. First trimester: No well-controlled human studies; animal studies not available. Second/third trimesters: Calcium gluconate is a physiologic electrolyte; deficiency may cause fetal skeletal abnormalities, but supplementation at recommended doses is unlikely to increase risk of major malformations. High doses may cause maternal hypercalcemia; risk of fetal hypoparathyroidism, tetany, and seizures if maternal calcium acutely increased. No known teratogenicity.
Potassium is a normal constituent of breast milk. Supplemental potassium does not affect milk potassium content. M/P ratio not applicable. Use with caution if maternal renal function impaired.
Excreted into breast milk; M/P ratio approximately 0.5. Considered compatible with breastfeeding in usual maternal doses. Monitor infant for signs of hypercalcemia if maternal doses are high.
No standard dose reduction required. Pharmacokinetic changes in pregnancy (increased GFR, blood volume) may increase potassium requirements or decrease serum levels; monitor and adjust dose to maintain normal serum potassium (3.5-5.0 m Eq/L).
Pregnancy-induced physiologic changes (increased plasma volume, increased GFR, placental calcium transfer) may lower maternal calcium levels; monitor and adjust dose as needed to maintain normal serum calcium. Intravenous doses typically require similar mg/kg dosing as non-pregnant; oral dosing may require a slight increase (10-20%) to compensate for increased demands and excretion. No standardized adjustment; individualized based on serum calcium levels.
Micro-K (potassium chloride extended-release) is used to prevent and treat hypokalemia. Avoid use in severe renal impairment, metabolic acidosis, or conditions with high potassium levels. Slow-release formulations reduce GI irritation but may be contraindicated in patients with GI motility disorders. Do not crush or chew capsules; administer with food and a full glass of water. Monitor serum potassium and renal function regularly.
Administer via slow IV push (1-2 m L/min) to avoid cardiac arrest; monitor ECG during infusion; do not mix with bicarbonate or phosphate solutions; extravasation causes tissue necrosis; use with caution in digitalis toxicity.
Take this medication with food and a full glass of water to reduce stomach upset.,Swallow the capsule whole; do not crush, chew, or open it.,Do not suddenly stop taking this medication without consulting your doctor.,Avoid salt substitutes or potassium-containing supplements unless approved by your doctor.,Seek immediate medical attention if you experience signs of high potassium levels: muscle weakness, irregular heartbeat, or tingling in hands/feet.
Report any pain, redness, or swelling at injection site immediately,Avoid taking calcium supplements or antacids containing calcium without consulting your doctor,Inform about any heart conditions, especially irregular heartbeat,May cause dizziness or fainting if infused too quickly
No interactions on record
"Calcium gluconate provides exogenous calcium, which can counteract the calcium channel blocking effect of nimodipine. This reduces nimodipine's ability to inhibit calcium influx into vascular smooth muscle cells, potentially decreasing its antihypertensive and vasodilatory efficacy. Clinically, coadministration may lead to reduced nimodipine effectiveness in preventing cerebral vasospasm after subarachnoid hemorrhage."
"Sodium glycerophosphate, an organic phosphate source, can chelate calcium ions in the gastrointestinal tract, forming insoluble calcium phosphate complexes. This reduces the absorption of orally administered calcium gluconate, leading to lower serum calcium concentrations. Clinically, this may result in diminished efficacy of calcium supplementation, potentially exacerbating hypocalcemia in susceptible patients."
"Calcium gluconate chelates deferiprone in the gastrointestinal tract, forming a non-absorbable complex that reduces deferiprone's bioavailability. This results in decreased serum concentrations and diminished therapeutic efficacy of deferiprone, potentially leading to inadequate chelation of iron in patients with iron overload. Clinically, patients may experience suboptimal reduction of serum ferritin and increased risk of iron-related organ damage."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MICRO-K vs CALCIUM GLUCONATE, answered by our medical review team.
MICRO-K is a Electrolyte Supplement (Potassium) that works by Potassium is the principal intracellular cation, essential for maintaining cellular tonicity, electrical neutrality, and enzymatic reactions. It modulates neuromuscular transmission, cardiac contractility, and acid-base balance.. CALCIUM GLUCONATE is a Electrolyte Supplement that works by Calcium gluconate dissociates to provide calcium ions, which are essential for nerve impulse transmission, muscle contraction, cardiac function, and blood coagulation. It acts as a mineral electrolyte replenisher.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MICRO-K and CALCIUM GLUCONATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MICRO-K is: Oral: 20-40 m Eq (1-2 capsules) two to four times daily; maximum 100 m Eq/day. Each capsule contains 8 m Eq (600 mg) of potassium chloride in a wax matrix extended-release formulation.. The standard adult dose of CALCIUM GLUCONATE is: Intravenous: 1-2 grams (10-20 m L of 10% solution) administered slowly over 5-10 minutes. May repeat based on serum calcium levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MICRO-K and CALCIUM GLUCONATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MICRO-K is classified as Category C. Potassium chloride (Micro-K) is not associated with major congenital malformations. Normal maternal serum potassium levels are required for fetal development. Hypokalemia or hyperk. CALCIUM GLUCONATE is classified as Category C. FDA Pregnancy Category C. First trimester: No well-controlled human studies; animal studies not available. Second/third trimesters: Calcium gluconate is a physiologic electrolyte; . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.